
Opinion|Videos|May 10, 2024
Oral SERDs in Development for ER+/HER2- Metastatic Breast Cancer
A breast medical oncologist reviews oral SERDs currently in development for the treatment of patients with ER+/HER2 metastatic breast cancer, highlighting camizestrant, imlunestrant, and giredestrant.
Advertisement
Episodes in this series

Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
FDA to Accept De-Identified Real-World Evidence for Select Medical Device Applications
2
FDA Approves Once-Monthly PCSK9 Injection for LDL-C Reduction
3
Bispecifics in New Combos, New Uses, and Earlier Lines of Treatment in Myeloma
4
COVID-19 Vaccination in Pregnant Patients Reduces Hospitalization, Preterm Birth Across Variants
5











































